OBJECTIVES: the aim of this study was to evaluate the long-term results of transcatheter balloon aortic valvuloplasty, the preferred treatment for congenital aortic stenosis (AS). BACKGROUND: aortic valve function and reintervention late after this procedure are not well characterized. METHODS: from 1985 to 2008, 563 patients underwent balloon dilation for congenital AS. After excluding those converted to univentricular circulation and/or died ≤ 30 days after the procedure, 509 patients constituted the study cohort. RESULTS: The median follow-up period was 9.3 years (range 0.1 to 23.6 years); cumulative follow-up was 5,003 patient-years. The median age was 2.4 years (range 1 day to 40.5 years), and most patients (73%) had isolated native AS. Peak AS gradients decreased significantly after dilation (median decrease, 35 mm Hg), and acute post-dilation aortic regurgitation was moderate or greater in 70 patients (14%). Older patients more often had post-dilation aortic regurgitation (p < 0.001). During follow-up, 225 patients (44%) underwent aortic valve reintervention: repeat balloon dilation in 115 (23%), aortic valve repair in 65 (13%), and aortic valve replacement in 116 (23%). Survival free from any aortic valve reintervention was 89 ± 1% at 1 year, 72 ± 2% at 5 years, 54 ± 3% at 10 years, and 27 ± 3% at 20 years. Freedom from aortic valve replacement was 90 ± 2% at 5 years, 79 ± 3% at 10 years, and 53 ± 4% at 20 years. In multivariate analyses, lower post-dilation AS gradient and lower grade of post-dilation aortic regurgitation were associated with longer freedom from aortic valve replacement, but age, era, and pre-dilation AS severity were not. CONCLUSIONS: although transcatheter aortic valvuloplasty is effective for relief of congenital AS, there are steady long-term hazards for surgical aortic valve reintervention and replacement that are independent of age at initial intervention or AS severity. 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: the aim of this study was to evaluate the long-term results of transcatheter balloon aortic valvuloplasty, the preferred treatment for congenital aortic stenosis (AS). BACKGROUND: aortic valve function and reintervention late after this procedure are not well characterized. METHODS: from 1985 to 2008, 563 patients underwent balloon dilation for congenital AS. After excluding those converted to univentricular circulation and/or died ≤ 30 days after the procedure, 509 patients constituted the study cohort. RESULTS: The median follow-up period was 9.3 years (range 0.1 to 23.6 years); cumulative follow-up was 5,003 patient-years. The median age was 2.4 years (range 1 day to 40.5 years), and most patients (73%) had isolated native AS. Peak AS gradients decreased significantly after dilation (median decrease, 35 mm Hg), and acute post-dilation aortic regurgitation was moderate or greater in 70 patients (14%). Older patients more often had post-dilation aortic regurgitation (p < 0.001). During follow-up, 225 patients (44%) underwent aortic valve reintervention: repeat balloon dilation in 115 (23%), aortic valve repair in 65 (13%), and aortic valve replacement in 116 (23%). Survival free from any aortic valve reintervention was 89 ± 1% at 1 year, 72 ± 2% at 5 years, 54 ± 3% at 10 years, and 27 ± 3% at 20 years. Freedom from aortic valve replacement was 90 ± 2% at 5 years, 79 ± 3% at 10 years, and 53 ± 4% at 20 years. In multivariate analyses, lower post-dilation AS gradient and lower grade of post-dilation aortic regurgitation were associated with longer freedom from aortic valve replacement, but age, era, and pre-dilation AS severity were not. CONCLUSIONS: although transcatheter aortic valvuloplasty is effective for relief of congenital AS, there are steady long-term hazards for surgical aortic valve reintervention and replacement that are independent of age at initial intervention or AS severity. 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Diego Porras; David W Brown; Rahul Rathod; Kevin Friedman; Kimberly Gauvreau; James E Lock; Jesse J Esch; Lisa Bergersen; Audrey C Marshall Journal: Congenit Heart Dis Date: 2013-10-15 Impact factor: 2.007
Authors: Allison C Hill; David W Brown; Steven D Colan; Kimberly Gauvreau; Pedro J del Nido; James E Lock; Rahul H Rathod Journal: Pediatr Cardiol Date: 2014-02-22 Impact factor: 1.655
Authors: Michael Farias; Kathy Jenkins; James Lock; Rahul Rathod; Jane Newburger; David W Bates; Dana G Safran; Kevin Friedman; Josh Greenberg Journal: Health Aff (Millwood) Date: 2013-05 Impact factor: 6.301
Authors: Kevin G Friedman; Doff B McElhinney; Steven D Colan; Diego Porras; Andrew J Powell; James E Lock; David W Brown Journal: Circ Cardiovasc Interv Date: 2012-06-26 Impact factor: 6.546
Authors: Sarah S Pickard; John B Wong; Emily M Bucholz; Jane W Newburger; Wayne Tworetzky; Terra Lafranchi; Carol B Benson; Louise E Wilkins-Haug; Diego Porras; Ryan Callahan; Kevin G Friedman Journal: Circ Cardiovasc Qual Outcomes Date: 2020-04-07